|
|
Vaccine Detail
|
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007037
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CEACAM5 - obsolete
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hodge et al., 2003)
- Detailed Gene Information: Click Here.
- Preparation: rF viruses were constructed by the insertion of foreign sequences into the BamHI J region of the genome of the POXVAC-TC strain of fowlpox virus (Hodge et al., 2003).
- Description: This is for Various Cancer (NCT00028496). A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the carcinoembryonic antigen (CEA) and a TRIad of COstimulatory Molecules (B7-1, ICAM-1 and LFA-3) (TRICOM). This agent may enhance CEA presentation to antigen presenting cells (APC) and activate cytotoxic T-cells against CEA-expressing tumors (NCI04) (NCIT_C2620).
|
| Host Response |
|
|
| References |
Hodge et al., 2003: Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9(5); 1837-1849. [PubMed: 12738742].
NCIT_C2620: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2620]
NCT00028496: [https://clinicaltrials.gov/ct2/show/NCT00028496?term=Recombinant+Fowlpox-CEA%286D%29%2FTRICOM+Vaccine&rank=1]
|
|
